Treatment of obesity hypertension and diabetes syndrome
Autor(a) principal: | |
---|---|
Data de Publicação: | 2001 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/11600/43901 https://doi.org/10.1161/01.HYP.38.3.705 |
Resumo: | Obesity has been shown to be an independent risk factor for coronary heart disease. The insulin resistance associated with obesity contributes to the development of other cardiovascular risk factors, including dyslipidemia, hypertension, and type 2 diabetes. The coexistence of hypertension and diabetes increases the risk for macrovascular and microvascular complications, thus predisposing patients to cardiac death, congestive heart failure, coronary heart disease, cerebral and peripheral vascular diseases, nephropathy, and retinopathy. Body weight reduction increases insulin sensitivity and improves both blood glucose and blood pressure control. Metformin therapy also improves insulin sensitivity and has been associated with decreases in cardiovascular events in obese diabetic patients. Antihypertensive treatment in diabetics decreases cardiovascular mortality and slows the decline in glomerular function. However, pharmacological treatment should take into account the effects of the antihypertensive agents on insulin sensitivity and lipid profile. Diuretics and P-blockers are reported to reduce insulin sensitivity and increase triglyceride levels, whereas calcium channel blockers are metabolically neutral and ACE inhibitors increase insulin sensitivity. For the high-risk hypertensive diabetic patients, ACE inhibition has proven to confer additional renal and vascular protection. Because hypertension and glycemic control are very important determinants of cardiovascular outcome in obese diabetic hypertensive patients, weight reduction, physical exercise, and a combination of antihypertensive and insulin sensitizers agents are strongly recommended to achieve target blood pressure and glucose levels. |
id |
UFSP_a243aa4f08c1a28e283edac7e8f6f33b |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/43901 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Zanella, Maria Teresa [UNIFESP]Kohlmann Junior, Osvaldo [UNIFESP]Ribeiro, Artur Beltrame [UNIFESP]Universidade Federal de São Paulo (UNIFESP)2018-06-15T17:38:28Z2018-06-15T17:38:28Z2001-09-01Hypertension. Philadelphia: Lippincott Williams & Wilkins, v. 38, n. 3, p. 705-708, 2001.0194-911Xhttp://repositorio.unifesp.br/11600/43901https://doi.org/10.1161/01.HYP.38.3.70510.1161/01.HYP.38.3.705WOS:000171308400036Obesity has been shown to be an independent risk factor for coronary heart disease. The insulin resistance associated with obesity contributes to the development of other cardiovascular risk factors, including dyslipidemia, hypertension, and type 2 diabetes. The coexistence of hypertension and diabetes increases the risk for macrovascular and microvascular complications, thus predisposing patients to cardiac death, congestive heart failure, coronary heart disease, cerebral and peripheral vascular diseases, nephropathy, and retinopathy. Body weight reduction increases insulin sensitivity and improves both blood glucose and blood pressure control. Metformin therapy also improves insulin sensitivity and has been associated with decreases in cardiovascular events in obese diabetic patients. Antihypertensive treatment in diabetics decreases cardiovascular mortality and slows the decline in glomerular function. However, pharmacological treatment should take into account the effects of the antihypertensive agents on insulin sensitivity and lipid profile. Diuretics and P-blockers are reported to reduce insulin sensitivity and increase triglyceride levels, whereas calcium channel blockers are metabolically neutral and ACE inhibitors increase insulin sensitivity. For the high-risk hypertensive diabetic patients, ACE inhibition has proven to confer additional renal and vascular protection. Because hypertension and glycemic control are very important determinants of cardiovascular outcome in obese diabetic hypertensive patients, weight reduction, physical exercise, and a combination of antihypertensive and insulin sensitizers agents are strongly recommended to achieve target blood pressure and glucose levels.Univ Fed Sao Paulo, Hosp Rim & Hipertensao, Div Nephrol, BR-04038002 Sao Paulo, BrazilUniv Fed Sao Paulo, Hosp Rim & Hipertensao, Div Endocrinol, BR-04038002 Sao Paulo, BrazilUniv Fed Sao Paulo, Hosp Rim & Hipertensao, Div Nephrol, BR-04038002 Sao Paulo, BrazilUniv Fed Sao Paulo, Hosp Rim & Hipertensao, Div Endocrinol, BR-04038002 Sao Paulo, BrazilWeb of Science705-708engLippincott Williams & WilkinsHypertensionobesitydiabetesdrug therapyTreatment of obesity hypertension and diabetes syndromeinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/439012021-10-04 21:23:54.006metadata only accessoai:repositorio.unifesp.br:11600/43901Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652021-10-05T00:23:54Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Treatment of obesity hypertension and diabetes syndrome |
title |
Treatment of obesity hypertension and diabetes syndrome |
spellingShingle |
Treatment of obesity hypertension and diabetes syndrome Zanella, Maria Teresa [UNIFESP] obesity diabetes drug therapy |
title_short |
Treatment of obesity hypertension and diabetes syndrome |
title_full |
Treatment of obesity hypertension and diabetes syndrome |
title_fullStr |
Treatment of obesity hypertension and diabetes syndrome |
title_full_unstemmed |
Treatment of obesity hypertension and diabetes syndrome |
title_sort |
Treatment of obesity hypertension and diabetes syndrome |
author |
Zanella, Maria Teresa [UNIFESP] |
author_facet |
Zanella, Maria Teresa [UNIFESP] Kohlmann Junior, Osvaldo [UNIFESP] Ribeiro, Artur Beltrame [UNIFESP] |
author_role |
author |
author2 |
Kohlmann Junior, Osvaldo [UNIFESP] Ribeiro, Artur Beltrame [UNIFESP] |
author2_role |
author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Zanella, Maria Teresa [UNIFESP] Kohlmann Junior, Osvaldo [UNIFESP] Ribeiro, Artur Beltrame [UNIFESP] |
dc.subject.eng.fl_str_mv |
obesity diabetes drug therapy |
topic |
obesity diabetes drug therapy |
description |
Obesity has been shown to be an independent risk factor for coronary heart disease. The insulin resistance associated with obesity contributes to the development of other cardiovascular risk factors, including dyslipidemia, hypertension, and type 2 diabetes. The coexistence of hypertension and diabetes increases the risk for macrovascular and microvascular complications, thus predisposing patients to cardiac death, congestive heart failure, coronary heart disease, cerebral and peripheral vascular diseases, nephropathy, and retinopathy. Body weight reduction increases insulin sensitivity and improves both blood glucose and blood pressure control. Metformin therapy also improves insulin sensitivity and has been associated with decreases in cardiovascular events in obese diabetic patients. Antihypertensive treatment in diabetics decreases cardiovascular mortality and slows the decline in glomerular function. However, pharmacological treatment should take into account the effects of the antihypertensive agents on insulin sensitivity and lipid profile. Diuretics and P-blockers are reported to reduce insulin sensitivity and increase triglyceride levels, whereas calcium channel blockers are metabolically neutral and ACE inhibitors increase insulin sensitivity. For the high-risk hypertensive diabetic patients, ACE inhibition has proven to confer additional renal and vascular protection. Because hypertension and glycemic control are very important determinants of cardiovascular outcome in obese diabetic hypertensive patients, weight reduction, physical exercise, and a combination of antihypertensive and insulin sensitizers agents are strongly recommended to achieve target blood pressure and glucose levels. |
publishDate |
2001 |
dc.date.issued.fl_str_mv |
2001-09-01 |
dc.date.accessioned.fl_str_mv |
2018-06-15T17:38:28Z |
dc.date.available.fl_str_mv |
2018-06-15T17:38:28Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Hypertension. Philadelphia: Lippincott Williams & Wilkins, v. 38, n. 3, p. 705-708, 2001. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/11600/43901 https://doi.org/10.1161/01.HYP.38.3.705 |
dc.identifier.issn.none.fl_str_mv |
0194-911X |
dc.identifier.doi.none.fl_str_mv |
10.1161/01.HYP.38.3.705 |
dc.identifier.wos.none.fl_str_mv |
WOS:000171308400036 |
identifier_str_mv |
Hypertension. Philadelphia: Lippincott Williams & Wilkins, v. 38, n. 3, p. 705-708, 2001. 0194-911X 10.1161/01.HYP.38.3.705 WOS:000171308400036 |
url |
http://repositorio.unifesp.br/11600/43901 https://doi.org/10.1161/01.HYP.38.3.705 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Hypertension |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
705-708 |
dc.publisher.none.fl_str_mv |
Lippincott Williams & Wilkins |
publisher.none.fl_str_mv |
Lippincott Williams & Wilkins |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1802764151470161920 |